Skip to main content
RT @BeckySueToo: #ACR22 KNOWLEDGE bowl Dr. Namrata Singh, a judge this year, lead the U Iowa team in their bowl champion

😷Dr. Rebecca Tuetken BeckySueToo

3 years 11 months ago
#ACR22 KNOWLEDGE bowl Dr. Namrata Singh, a judge this year, lead the U Iowa team in their bowl championship 3-peet, 2014, ‘15 & ‘16.
RT @debconstien: Attending Difficult to treat RA…looking forward to learning new things about this. #Gowithus #ACR22

Deb Constien debconstien

3 years 11 months ago
Attending Difficult to treat RA…looking forward to learning new things about this. #Gowithus #ACR22 @IFAiArthritis https://t.co/ChET0ckm0X
RT @drdavidliew: @erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results.

It's n

David Liew drdavidliew

3 years 11 months ago
@erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results. It's not just pain differences - but that's real too. It's lots of things, but whatever the case we ignore sex and gender's impact in RA at our peril. ABST0532 #ACR22 @Janetbirdope @TheLancetRheum @RheumNow https://t.co/27uQmNAlPF
RT @RHEUMarampa: How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines:
💉Pre-vax:
💊csDMA

sheila RHEUMarampa

3 years 11 months ago
How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines: 💉Pre-vax: 💊csDMARDs - hold time 4 wks 💊bDMARDs -hold time of one dosing interval 💉Post-vax: hold DMARDs for 4 wks #ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC
RT @uptoTate: #ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after

Dr. Rachel Tate uptoTate

3 years 11 months ago
#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf
RT @synovialjoints: Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR

Dr. Antoni Chan synovialjoints

3 years 11 months ago
Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ
Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.
RT @drdavidliew: I've always presumed biopsy-neg GCA just hit skip lesions sections

What does RNA-Seq of temporal arter

David Liew drdavidliew

3 years 11 months ago
I've always presumed biopsy-neg GCA just hit skip lesions sections What does RNA-Seq of temporal artery bx tell us? positive bx similar to skip lesions bx neg GCA very different Sometimes it's not just the sampling sometimes it's something different... ABST0486 #ACR22 @RheumNow https://t.co/QITgkZ21sy
RT @doctorRBC: Bimekizumab (IL-17A and IL-17F inhibitor) use in non-radiographic AxSpA resulted in rapid improvement of

Robert B Chao, MD doctorRBC

3 years 11 months ago
Bimekizumab (IL-17A and IL-17F inhibitor) use in non-radiographic AxSpA resulted in rapid improvement of ASAS40 along with reduction in SPARCC MRI SI joint inflammation #Abs0544 @RheumNow #ACR22 https://t.co/pOCg0idGsR
RT @RHEUMarampa: 2022 ACR guide for #vaccinations in RMD pts:
💉Influenza:⬆️dose or adjuvant (CR) >=65 & &g

sheila RHEUMarampa

3 years 11 months ago
2022 ACR guide for #vaccinations in RMD pts: 💉Influenza:⬆️dose or adjuvant (CR) >=65 & >18<65 on immunosuppressives 💉Pneumococcal: SR for <65 yrs, on immunosuppressives 💉Rec VZV: SR for >18y on immunosupressives 💉HPV: CR for >26y & <45y on meds & no prev vax #ACR22 @rheumnow https://t.co/2DlIqNUBct
RT @drdavidliew: What do you look for on temporal artery examination in GCA assessment?

tenderness: minimally useful
re

David Liew drdavidliew

3 years 11 months ago
What do you look for on temporal artery examination in GCA assessment? tenderness: minimally useful reduced/absent pulse or thickening: quite good if there, nearly as good as halo Good examination is powerful, if you're doing it right! ABST0483 Salvarani group #ACR22 @RheumNow https://t.co/B3qvSW68at
RT @uptoTate: Abs 0406 demonstrates stronger relationship between disease activity (using BASFI and BASDAI) and quality

Dr. Rachel Tate uptoTate

3 years 11 months ago
Abs 0406 demonstrates stronger relationship between disease activity (using BASFI and BASDAI) and quality of life in men w/ axSpA than women. IMO, it also demonstrates need for better assessment tools for women! #ACR22 @RheumNow https://t.co/B44ZixyeAJ https://t.co/lMzpsGcsFM
Rheumatoid arthritis is known to be associated with a higher risk of infections. In abstract 0535, Porter and colleagues have assessed infection rates in the pre-RA and early RA phases as defined by antibiotics prescription and hospital admissions with an infection main diagnostic code in the UK National database.
RT @uptoTate: Abs0399 ASAS recs for requesting/reporting imaging in suspected AxSpA pts key takeaway: communication!
Rhe

Dr. Rachel Tate uptoTate

3 years 11 months ago
Abs0399 ASAS recs for requesting/reporting imaging in suspected AxSpA pts key takeaway: communication! Rheum provides pertinent hx (trauma, childbirth, pain location, duration, etc), DDx Rads summarize hx & give pertinent +/- exam findings #ACR22 @RheumNow https://t.co/Ucr8B5xfGA https://t.co/F6g15dQhj1
RT @doctorRBC: 2022 ASAS-EULAR Recommendations of AxSpA management
1) NSAIDs still first line
2) Analgesics/opioids cont

Robert B Chao, MD doctorRBC

3 years 11 months ago
2022 ASAS-EULAR Recommendations of AxSpA management 1) NSAIDs still first line 2) Analgesics/opioids contraindicated 3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs 4) Tapering but not discontinuation of bDMARDs in sustained remission Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v
×